Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.
Publication|Articles|August 19, 2026
- Pharmaceutical Executive: August 2026
- Volume 46
- Issue 6
Pharmaceutical Executive: August 2026 Interactive Digital Edition
View the Pharmaceutical Executive August 2026 issue in an interactive format.
Advertisement
Click
Articles in this issue
about 1 month ago
More Than Titlesabout 2 months ago
2026 Pharm Exec Top 50 Companiesabout 2 months ago
From Value Imperative to Operating Reality: Rethinking Trust in Pharmaabout 2 months ago
2026 Emerging Pharma Leadersabout 2 months ago
Making the Smart Career Movesabout 2 months ago
Two Decades of Technology Transformation in Pharmaabout 2 months ago
Finding the Universal Truth in a Drug's Storyabout 2 months ago
Preventing Cardiovascular Disease Through Mission-Driven Leadershipabout 2 months ago
What C-Suite Readiness Really RequiresAdvertisement
Related to this article
While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz
2
Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch
3
The Legacy of Rutledge: How States and Congress Can Still Regulate Pharmacy Benefit Managers
4
Your Questions Answered: Two FDA Approvals, Six Platform Deals, and a European Warning
5